LC-MS/MS ASSAY FOR IRBESARTAN IN HUMAN PLASMA USING SOLID PHASE EXTRACTION TECHNIQUE: A PHARMACOKINETIC STUDY

  • Mahitej Yadav Katteboina Jawaharlal Nehru Technological University Hyderabad
  • Nageswara Rao Pilli Jawaharlal Nehru Technological University Hyderabad
  • Jaswanth Kumar Inamadugu Jawaharlal Nehru Technological University Hyderabad
  • Shobha Rani Satla Center for Pharmaceutical Sciences, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad 500085, India

Abstract

Objective: The objective of this research was to develop a novel liquid chromatography/tandem mass spectrometry (LC-MS/MS) method for the determination of irbesartan in human plasma.

Methods: An analytical method based on liquid chromatography/tandem mass spectrometry (LC-MS/MS) has been developed and validated for the quantitative determination of irbesartan in human plasma. The method utilizes irbesartan d4 as internal standard (IS). After solid phase extraction (SPE), analyte and the IS were chromato graphed on a C18 columns using a isocratic mobile phase composed of methanol–0.2% formic acid (85:15, v/v) pumped at a flow rate of 0.70 mL/min.

Results: Precision and accuracy of the method was determined using five analytical batches in the concentration range of 50.0–9982 ng/ml. All the validation experiments were carried out as per the US FDA guidelines and results met the acceptance criteria.

Conclusion: The proposed LC–MS/MS assay method is simple, rapid and enough sensitive for the determination of irbesartan in human plasma. A chromatographic run time set at 2.0 min, thus can analyze more than 300 samples in a day. Also, the proposed method was found to be applicable to clinical studies.

 
Keywords: Irbesartan, Solid–phase extraction (SPE), LC-MS/MS, Method validation, Pharmacokinetics

Downloads

Download data is not yet available.

References

1. Burnier M, Brunner HR. Angiotensin II receptor antagonists. Lancet 2000;355:637-45.
2. Marino MR, Langenbacher K, Ford NF, Uderman HD. Pharmacokinetics and pharmacodynamics of irbesartan in healthy subjects. J Clin Pharmacol 1998;38:246-55.
3. Tutunji LF, Tutunji MF, Alzoubi MI, Khabbas MH, Arida AI. Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma using HPLC coupled with tandem mass spectrometry: Application to bioequivalence studies. J Pharm Biomed Anal 2010;51:985-90.
4. Prasad SVSGB, Shivakumar S, Sudhir T, Mital R, Devala Rao G. LC/MS/MS method for the simultaneous estimation of losartan potassium and irbesartan in rat plasma. Int J Pharm Pharm Sci 2009;1:206-15.
5. Ganesan M, Nanjundan S, Gomathi M, Muralidharan S. Method development and validation of irbesartan using LCMS/MS: Application to pharmacokinetic studies. J Chem Pharm Res 2010;2:740-6.
6. Ferreirós N, Dresen S, Alonso RM, Weinmann W. Validated quantitation of angiotensin II receptor antagonists (ARA-II) in human plasma by liquid-chromatography-tandem mass spectrometry using minimum sample clean-up and investigation of ion suppression. Ther Drug Monit 2007;29:824-34.
7. Tiwari HK, Monif T, Verma PRP, Reyar S, Khuroo AH, Mishra S. Quantitative estimation of irbesartan in two different matrices and its application to human and dog bioavailability studies using LC–MS/MS. Asian J Pharm Sci 2013;8:346-55.
8. Wani TA, Zargar S. New ultra-performance liquid chromatography-tandem mass spectrometry method for the determination of irbesartan in human plasma. J Food Drug Anal 2015. doi: 10.1016/j.jfda.2015.02.008. [Article in Press]
9. Qiu X, Wang Z, Wang B, Zhan H, Pan X, Xu RA. Simultaneous determination of irbesartan and hydrochlorothiazide in human plasma by ultra-high performance liquid chromatography tandem mass spectrometry and its application to a bioequivalence study. J Chromatogr B: Anal Technol Biomed Life Sci 2014;957:110-5.
10. Lu CY, Feng CH. Quantitation of irbesartan and major proteins in human plasma by mass spectrometry with time-of-flight analyzer. J Pharm Biomed Anal 2011;54:100-5.
11. Shah RP, Sahu A, Singh S. Identification and characterization of degradation products of irbesartan using LC-MS/TOF, MS(n), on-line H/D exchange and LC-NMR. J Pharm Biomed Anal 2010;51:1037-46.
12. Kalovidouris M, Michalea S, Robola N, Koutsopoulou M, Panderi I. Ultra-performance liquid chromatography/tandem mass spectrometry method for the determination of lercanidipine in human plasma. Rapid Commun Mass Spectrom 2006;20:2939–46.
13. Chen L, Qin F, Ma Y, Li F. Quantitative determination of azithromycin in human plasma by ultra-performance liquid chromatography–electrospray ionization mass spectrometry and its application in a pharmacokinetic study. J Chromatogr B 2007;855:255–61.
14. US DHHS, FDA and CDER. Guidance for Industry: Bioanalytical Method Validation. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research and Center for Veterinary Medicine; 2001. Available from: URL: http://www/fda.gov/cder/ guidance/index.htm. [Last accessed on 20 May 2015].
Statistics
572 Views | 1009 Downloads
How to Cite
Katteboina, M. Y., N. R. Pilli, J. K. Inamadugu, and S. R. Satla. “LC-MS/MS ASSAY FOR IRBESARTAN IN HUMAN PLASMA USING SOLID PHASE EXTRACTION TECHNIQUE: A PHARMACOKINETIC STUDY”. International Journal of Pharmacy and Pharmaceutical Sciences, Vol. 7, no. 9, July 2015, pp. 335-40, https://innovareacademics.in/journals/index.php/ijpps/article/view/7624.
Section
Original Article(s)